€ million |
|
Q3 2025 |
|
Q3 2026 |
|
9M 2025 |
|
9M 2026 |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales |
|
9,660 |
|
10,053 |
|
34,137 |
|
34,330 |
|||
Cost of goods sold |
|
(4,307) |
|
(4,601) |
|
(14,296) |
|
(14,373) |
|||
Gross profit |
|
5,353 |
|
5,452 |
|
19,841 |
|
19,957 |
|||
Selling expenses |
|
(2,923) |
|
(3,457) |
|
(9,114) |
|
(10,023) |
|||
Research and development expenses |
|
(1,498) |
|
(1,432) |
|
(4,364) |
|
(4,369) |
|||
General administration expenses |
|
(482) |
|
(559) |
|
(1,543) |
|
(1,652) |
|||
Other operating income |
|
316 |
|
575 |
|
1,223 |
|
1,930 |
|||
Other operating expenses |
|
(1,309) |
|
(689) |
|
(4,249) |
|
(1,598) |
|||
EBIT1 |
|
(543) |
|
(110) |
|
1,794 |
|
4,245 |
|||
Equity-method income (loss) |
|
14 |
|
(31) |
|
(13) |
|
(32) |
|||
Financial income |
|
130 |
|
113 |
|
302 |
|
360 |
|||
Financial expenses |
|
(762) |
|
(760) |
|
(1,840) |
|
(2,051) |
|||
Financial result |
|
(618) |
|
(678) |
|
(1,551) |
|
(1,723) |
|||
Income before income taxes |
|
(1,161) |
|
(788) |
|
243 |
|
2,522 |
|||
Income taxes |
|
202 |
|
127 |
|
(88) |
|
(187) |
|||
Income after income taxes |
|
(959) |
|
(661) |
|
155 |
|
2,335 |
|||
of which attributable to noncontrolling interest |
|
4 |
|
11 |
|
18 |
|
25 |
|||
of which attributable to Bayer AG stockholders (net income) |
|
(963) |
|
(672) |
|
137 |
|
2,310 |
|||
|
|
|
|
|
|
|
|
|
|||
€ |
|
|
|
|
|
|
|
|
|||
Earnings per share |
|
|
|
|
|
|
|
|
|||
Basic |
|
(0.98) |
|
(0.69) |
|
0.14 |
|
2.35 |
|||
Diluted |
|
(0.98) |
|
(0.69) |
|
0.14 |
|
2.35 |
|||
|
|||||||||||